Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
HDAC1 56.0 nM (IC50) HDAC2 90.0 nM (IC50) HDAC3 422.2 nM (IC50)
|
---|---|
ln Vitro |
In comparison to MS-275 (HY-12163), HDAC-IN-56 exhibits more effective and specific inhibition against Class I HDACs 1, 2, and 3. HDAC-IN-56 (0.1 μM, 2 h) was stable in five species of hepatocytes and metabolized differently in human, monkey, dog, rat, and mouse hepatocytes[1]. Apoptosis and G1 cell cycle arrest are efficiently induced by HDAC-IN-56 (0.01-1 μM, 72 h)[1]. The intracellular level of acetyl-histone H3 and p21 is increased more by HDAC-IN-56 (0.01-1 μM, 72 h) treatment than by Tucidinostat (HY-109015) or MS-275 (HY-12163), indicating a substantial inhibition of class I histone deacetylase[1]. For SKM-1, HDAC-IN-56's IC50 is 139.0 ± 8.0 nM[1]. In comparison to MS-275 (HY-12163), HDAC-IN-56 exhibits more effective and specific inhibition against Class I HDACs 1, 2, and 3. HDAC-IN-56 (0.1 μM, 2 h) was stable in five species of hepatocytes and metabolized differently in human, monkey, dog, rat, and mouse hepatocytes[1]. Apoptosis and G1 cell cycle arrest are efficiently induced by HDAC-IN-56 (0.01-1 μM, 72 h)[1]. The intracellular level of acetyl-histone H3 and p21 is increased more by HDAC-IN-56 (0.01-1 μM, 72 h) treatment than by Tucidinostat (HY-109015) or MS-275 (HY-12163), indicating a substantial inhibition of class I histone deacetylase[1]. For SKM-1, HDAC-IN-56's IC50 is 139.0 ± 8.0 nM[1].
|
ln Vivo |
Even at the high dose of 80 mg/kg per day, HDAC-IN-56 (10-80 mg/kg/d, po, one month) did not result in appreciable changes in body weight [1]. In ICR mice and SD rats, respectively, HDAC-IN-56 (SD: 10, 20 mg/kg; ICR: 20, 40 mg/kg, po) has favorable pharmacokinetic properties and oral bioavailability. stand at 39.5% and 47.7%[1]. The expected inhibitory impact of HDAC-IN-56 (20–60 mg/kg, po) on the formation of tumors in nude mice MC38 cells is observed. A more pronounced tumor growth suppression effect was observed at the same dose when transplanted into immunocompetent C57BL/6 mice, suggesting that HDAC-IN-56 may somehow activate and engage the immune system to produce a larger anti-tumor impact[1].
|
Animal Protocol |
Animal/Disease Models: Male SD rats or ICR mice[1]
Doses: 10, 20 mg/kg; ICR: 20, 40 mg/kg Route of Administration: Male SD rats or ICR mice (n = 6) were fasted for 12 h before administration and remained fasting for 2 h. SD rats were received 10 and 20 mg/kg via intravenously (iv) injection (iv) and oral administration (po), respectively, and ICR mice were received 20 and 40 mg/kg via intravenously (iv) injection (iv) and oral administration (po), respectively. Experimental Results: Epresented a favorable pharmacokinetic/PK profile with an oral bioavailability of 47.7% in ICR mice and 39.5% in SD rat, respectively Animal/Disease Models: SKM-1 or MC-38 cells xenograft model[1] Doses: 20, 40, 60 mg/kg Route of Administration: po (oral gavage). Experimental Results: Inhibited the tumor growth of MC38 cells in nude mice. demonstrated more significant tumor growth inhibition at the same doses, which implie that the immune system may be engaged and somehow activated HDAC-IN-56 to gain stronger antitumor effect. |
References |
[1]. Li D, et al. Discovery of (S)-N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6H)-yl)ethyl) benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate. J Med Chem. 2023 May 25;66(10):7016-7037.
|
Molecular Formula |
C28H28FN5O2
|
---|---|
Molecular Weight |
485.55
|
CAS # |
2814571-89-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0595 mL | 10.2976 mL | 20.5952 mL | |
5 mM | 0.4119 mL | 2.0595 mL | 4.1190 mL | |
10 mM | 0.2060 mL | 1.0298 mL | 2.0595 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.